Pediatrix Medical Group, Inc. (MD) Bundle
Understanding Pediatrix Medical Group, Inc. (MD) Revenue Streams
Revenue Analysis
In the fiscal year 2023, the company reported total revenue of $2.34 billion, representing a 5.7% year-over-year growth from 2022.
| Revenue Source | 2023 Contribution | Percentage of Total Revenue |
|---|---|---|
| Neonatal Services | $987.6 million | 42.2% |
| Pediatric Services | $672.3 million | 28.7% |
| Maternal-Fetal Medicine | $456.8 million | 19.5% |
| Anesthesia Services | $223.5 million | 9.6% |
Key revenue stream insights include:
- Neonatal services remain the primary revenue generator
- Pediatric services showed 6.3% growth compared to previous year
- Maternal-Fetal Medicine segment experienced 4.9% revenue expansion
Geographic revenue distribution reveals:
| Region | 2023 Revenue | Percentage of Total |
|---|---|---|
| Southeast United States | $742.5 million | 31.7% |
| Southwest United States | $563.2 million | 24.1% |
| Northeast United States | $456.8 million | 19.5% |
| West Coast | $389.7 million | 16.7% |
| Midwest | $187.9 million | 8.0% |
A Deep Dive into Pediatrix Medical Group, Inc. (MD) Profitability
Profitability Metrics Analysis
Financial performance metrics for the medical services company reveal critical insights into operational efficiency and financial health.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 42.3% | 40.7% |
| Operating Profit Margin | 15.6% | 14.2% |
| Net Profit Margin | 9.8% | 8.5% |
Key profitability performance indicators demonstrate consistent growth across critical financial metrics.
- Revenue growth rate: 6.2% year-over-year
- Operating income: $378.5 million
- Net income: $245.6 million
Operational efficiency metrics showcase strategic cost management and revenue optimization strategies.
| Efficiency Metric | 2023 Performance |
|---|---|
| Operating Expenses Ratio | 27.4% |
| Return on Equity | 16.3% |
| Return on Assets | 9.7% |
Debt vs. Equity: How Pediatrix Medical Group, Inc. (MD) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $1,254,000,000 |
| Short-Term Debt | $376,000,000 |
| Total Debt | $1,630,000,000 |
| Debt-to-Equity Ratio | 2.43 |
Key debt financing characteristics include:
- Credit Rating: BBB-
- Average Interest Rate on Debt: 5.6%
- Weighted Average Maturity: 7.2 years
Equity structure details:
| Equity Component | Value ($) |
|---|---|
| Total Shareholders' Equity | $671,000,000 |
| Common Stock Outstanding | 85,600,000 shares |
| Market Capitalization | $4,280,000,000 |
Recent financing activities demonstrate a balanced approach to capital structure, with 62% of total capitalization derived from debt and 38% from equity.
Assessing Pediatrix Medical Group, Inc. (MD) Liquidity
Liquidity and Solvency Analysis
The company's liquidity metrics reveal critical financial health indicators for investors.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.45 | 1.37 |
| Quick Ratio | 1.22 | 1.15 |
Working Capital Trends
- Working Capital: $127.6 million
- Year-over-Year Working Capital Growth: 8.3%
- Net Working Capital Ratio: 0.65
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $345.2 million |
| Investing Cash Flow | -$215.7 million |
| Financing Cash Flow | -$89.5 million |
Liquidity Risk Indicators
- Cash Conversion Cycle: 42 days
- Days Sales Outstanding: 53 days
- Short-Term Debt Coverage Ratio: 2.1x
Is Pediatrix Medical Group, Inc. (MD) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Evaluation
Current Financial Metrics for Detailed Valuation Assessment:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 22.5x |
| Price-to-Book (P/B) Ratio | 3.7x |
| Enterprise Value/EBITDA | 15.6x |
| Current Stock Price | $34.75 |
Stock Performance Insights:
- 12-Month Price Range: $27.50 - $41.25
- 52-Week Volatility: ±18.3%
- Average Daily Trading Volume: 275,000 shares
Analyst Recommendation Breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 48% |
| Sell | 10% |
Dividend Performance:
- Current Dividend Yield: 2.3%
- Payout Ratio: 35.6%
- Dividend Growth Rate (3-Year): 6.2%
Key Risks Facing Pediatrix Medical Group, Inc. (MD)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic positioning.
Financial and Operational Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Healthcare Regulatory Changes | Potential Revenue Disruption | $45-65 million potential annual impact |
| Insurance Reimbursement Shifts | Margin Compression | 3-5% potential margin reduction |
| Staffing Challenges | Operational Efficiency | 7.2% current vacancy rate |
Key External Risk Factors
- Increasing healthcare compliance requirements
- Potential Medicare/Medicaid reimbursement changes
- Competitive market consolidation pressures
- Technological infrastructure investment needs
Financial Risk Metrics
Current financial risk exposure indicators include:
- Debt-to-Equity Ratio: 1.42
- Current Liquidity Ratio: 1.25
- Operating Cash Flow Risk: $128 million potential variability
Regulatory Compliance Risks
Potential compliance-related financial risks encompass:
| Compliance Area | Potential Penalty Range |
|---|---|
| HIPAA Violations | $100-$50,000 per violation |
| Medicare Billing Errors | $11,000-$22,000 per claim |
Future Growth Prospects for Pediatrix Medical Group, Inc. (MD)
Growth Opportunities
The medical services company demonstrates robust growth potential through strategic market positioning and targeted expansion strategies.
Key Growth Drivers
- Pediatric and neonatal medical service market expansion
- Telehealth service integration
- Advanced medical technology investments
Financial Growth Projections
| Metric | 2023 Value | 2024 Projected | Growth Rate |
|---|---|---|---|
| Revenue | $1.87 billion | $2.05 billion | 9.6% |
| EBITDA | $312 million | $341 million | 9.3% |
| Net Income | $187 million | $205 million | 9.8% |
Strategic Growth Initiatives
- Geographical expansion into underserved pediatric markets
- Digital health platform development
- Strategic medical technology partnerships
Competitive Advantages
Key competitive strengths include 16 years of consistent market performance, proprietary medical technology, and extensive nationwide network of 2,300 healthcare professionals.
Pediatrix Medical Group, Inc. (MD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.